Atopic dermatitis (AD) is a chronic inflammatory skin disease caused by a damaged skin barrier due to hereditary and/or immunological factors involving T-helper cell activation. Diagnosis is clinical, and the patient must meet specific criteria to be diagnosed with AD. Scoring scales such as the Eczema Severity Index Score (EASI) have been developed to assess the extent and severity of AD. Treatment of AD consists of emollients, topical corticosteroids, calcineurin inhibitors, and phototherapy. For moderate to severe AD, systemic treatments such as interleukin inhibitors, cyclosporine, methotrexate, and Janus kinase inhibitors (JAK inhibitors) are used. A receptor called ox40, found on T-helper cells, has its ligand on antigen-presenting cells (APC). Activation of the ox40 receptor plays a significant role in the activation and lifespan of T-cells and has been found to play an important role in T-helper cell-driven inflammatory diseases such as AD. Inhibiting the ox40-ox40L interaction with antibodies that block ox40, such as rocatinlimab, telazorlimab, or ox40L, such as amlitelimab, is seen as a potential new treatment for AD.
The aim of this literature study was to evaluate optimal doses for different drug candidates inhibiting the ox40-ox40L interaction in the treatment of moderate to severe AD. Five different studies evaluating the efficacy and safety of various doses of anti-ox40/ox40L, sourced from the scientific search engine PubMed, were used in the literature study.
The results from the studies showed that the studied substances had different optimal doses for statistically significant reduction in EASI: rocatinlimab 300 mg/2 weeks, telazorlimab 300 mg/2 weeks, and amlitelimab 100 mg/4 weeks. All had tolerable side effects and showed a statistically significant improvement in symptoms in patients with moderate to severe AD, but anti-ox40L, amlitelimab had the greatest effect despite lower doses administered every four weeks compared to other substances. However, the study evaluating amlitelimab had far fewer participants compared to the others, so further studies are needed to assess the efficacy and safety of amlitelimab.